In yet another power play, ALPHAEON Corporation has acquired the worldwide licensing rights to TouchMD, an interactive software platform that helps educate prospective patients before, during, and after their consultation.
ALPHAEON, a wholly owned subsidiary of Strathspey Crown Holdings LLC, has garnered its of headlines of late. The company very recently acquired Evolus Inc of Santa Barbara, California. As part of the transaction, it received the exclusive license to market the botulinum toxin Type A product EVOSYAL in both the US and several international markets. In August 2013, ALPHAEON acquired exclusive US license to TEOXANE Laboratories’ full portfolio of next-generation Hyaluronic acid (HA)-based dermal fillers and cosmeceutical products.
If approved, EVOSYAL and TEOSYAL will be marketed side by side both in the US and internationally.
The American Society of Plastic Surgeons partnered with Strathspey Crown Holdings LLC earlier this year to provide additional capital to members so they have the resources to compete with cosmetic surgery franchises.
